Stanisław Szala

1.8k total citations
78 papers, 1.4k citations indexed

About

Stanisław Szala is a scholar working on Molecular Biology, Cancer Research and Immunology. According to data from OpenAlex, Stanisław Szala has authored 78 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 21 papers in Cancer Research and 17 papers in Immunology. Recurrent topics in Stanisław Szala's work include Angiogenesis and VEGF in Cancer (15 papers), RNA Interference and Gene Delivery (13 papers) and Cancer, Hypoxia, and Metabolism (12 papers). Stanisław Szala is often cited by papers focused on Angiogenesis and VEGF in Cancer (15 papers), RNA Interference and Gene Delivery (13 papers) and Cancer, Hypoxia, and Metabolism (12 papers). Stanisław Szala collaborates with scholars based in Poland, United States and France. Stanisław Szala's co-authors include Tomasz Cichoń, Ryszard Smolarczyk, Aleksander Sochanik, Magdalena Jarosz–Biej, Hilary Koprowski, Alban J. Linnenbach, Yasushi Kasai, Iwona Mitrus, Sybilla Matuszczak and Zenon Steplewski and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and PLoS ONE.

In The Last Decade

Stanisław Szala

74 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanisław Szala Poland 20 842 345 313 196 164 78 1.4k
Keishi Fujiwara Japan 21 983 1.2× 316 0.9× 319 1.0× 153 0.8× 248 1.5× 38 2.0k
Atsushi Kondo Japan 21 864 1.0× 254 0.7× 222 0.7× 139 0.7× 144 0.9× 109 1.6k
Klaus Eckert Germany 21 971 1.2× 170 0.5× 307 1.0× 79 0.4× 103 0.6× 65 1.5k
Ulf Brockmeier Germany 18 851 1.0× 579 1.7× 357 1.1× 230 1.2× 200 1.2× 32 1.8k
Wojciech Jóźwicki Poland 23 525 0.6× 402 1.2× 436 1.4× 158 0.8× 179 1.1× 63 1.8k
Geethani Bandara United States 23 709 0.8× 618 1.8× 156 0.5× 313 1.6× 80 0.5× 42 1.7k
Remco van Horssen Netherlands 16 678 0.8× 300 0.9× 293 0.9× 84 0.4× 257 1.6× 20 1.6k
Marta Compte Spain 22 858 1.0× 415 1.2× 563 1.8× 125 0.6× 267 1.6× 42 1.7k
Richard M. Leimgruber United States 17 1.4k 1.6× 144 0.4× 252 0.8× 154 0.8× 373 2.3× 27 2.0k
T. Muramatsu Japan 24 1.6k 2.0× 216 0.6× 273 0.9× 224 1.1× 236 1.4× 36 2.5k

Countries citing papers authored by Stanisław Szala

Since Specialization
Citations

This map shows the geographic impact of Stanisław Szala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanisław Szala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanisław Szala more than expected).

Fields of papers citing papers by Stanisław Szala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanisław Szala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanisław Szala. The network helps show where Stanisław Szala may publish in the future.

Co-authorship network of co-authors of Stanisław Szala

This figure shows the co-authorship network connecting the top 25 collaborators of Stanisław Szala. A scholar is included among the top collaborators of Stanisław Szala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanisław Szala. Stanisław Szala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cichoń, Tomasz, Justyna Czapla, Magdalena Jarosz–Biej, et al.. (2021). Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma. Scientific Reports. 11(1). 18335–18335. 19 indexed citations
2.
Jarosz–Biej, Magdalena, Sybilla Matuszczak, Tomasz Cichoń, et al.. (2018). M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma. PLoS ONE. 13(1). e0191012–e0191012. 64 indexed citations
3.
Jarosz–Biej, Magdalena, Ryszard Smolarczyk, Tomasz Cichoń, et al.. (2015). Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice. Archivum Immunologiae et Therapiae Experimentalis. 63(6). 451–464. 11 indexed citations
4.
Szala, Stanisław, Sybilla Matuszczak, Justyna Czapla, & Ewa Wiśniewska. (2014). From precursor to reprogrammed cells: evolution of cardiomyoplasty. Postępy Higieny i Medycyny Doświadczalnej. 68. 153–161. 1 indexed citations
5.
Mitrus, Iwona, Tomasz Cichoń, Ryszard Smolarczyk, et al.. (2013). Antitumor Effects of Recombinant Antivascular Protein ABRaA-VEGF121 Combined with IL-12 Gene Therapy. Archivum Immunologiae et Therapiae Experimentalis. 62(2). 161–168. 8 indexed citations
6.
Mitrus, Iwona, et al.. (2012). Evolving models of tumor origin and progression. Tumor Biology. 33(4). 911–917. 17 indexed citations
7.
Mitrus, Iwona, et al.. (2012). Properties of B16-F10 murine melanoma cells subjected to metabolic stress conditions.. Acta Biochimica Polonica. 59(3). 363–6. 5 indexed citations
8.
Szala, Stanisław, Iwona Mitrus, & Aleksander Sochanik. (2010). Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?. Cancer Immunology Immunotherapy. 59(10). 1449–1455. 13 indexed citations
9.
Cichoń, Tomasz, et al.. (2009). Chimeric protein ABRaA-VEGF121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth.. Acta Biochimica Polonica. 56(1). 115–24. 9 indexed citations
10.
Smolarczyk, Ryszard, Tomasz Cichoń, & Stanisław Szala. (2009). [Peptides: a new class of anticancer drugs].. PubMed. 63. 360–8. 14 indexed citations
11.
Szala, Stanisław. (2008). Rola leków antyangiogennych w wielolekowej terapii nowotworów. Via Medica Journals. 4(1). 1–7.
12.
Szala, Stanisław, et al.. (2006). VEGFR-2 receptor – target for anticancer therapy. Contemporary Oncology/Współczesna Onkologia. 10(10). 506–514. 1 indexed citations
13.
Olbryt, Magdalena, Michał Jarząb, Joanna Jazowiecka-Rakus, et al.. (2006). Gene Expression Profile of B16(F10) Murine Melanoma Cells Exposed to Hypoxic Conditions In Vitro. Gene Expression. 13(3). 191–203. 32 indexed citations
14.
Szala, Stanisław. (2004). Two-Domain Vascular Disruptive Agents in Cancer Therapy. Current Cancer Drug Targets. 4(6). 501–509. 4 indexed citations
15.
Szary, Jarosław & Stanisław Szala. (2001). Intra‐tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. International Journal of Cancer. 91(6). 835–839. 2 indexed citations
16.
Budryk, Magdalena, Tomasz Cichoń, & Stanisław Szala. (2001). Direct in vivo transfer of plasmid DNA into murine tumors: effects of endotoxin presence and transgene localization.. Acta Biochimica Polonica. 48(3). 795–800. 2 indexed citations
17.
Szala, Stanisław. (2000). Specific induction of apoptosis in cancer cells. Nowotwory Journal of Oncology. 50(2). 111–111. 1 indexed citations
18.
Budryk, Magdalena, et al.. (2000). Direct transfer of IL-12 gene into growing Renca tumors.. Acta Biochimica Polonica. 47(2). 385–391. 11 indexed citations
19.
Sochanik, Aleksander, et al.. (1995). Introduction of murine Il-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Letters. 97(2). 189–193. 21 indexed citations
20.
Szala, Stanisław, Wincenty Kilarski, & M Choraźy. (1970). The fast-renaturing fraction of calf thymus DNA.. PubMed. 17(3). 191–202. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keishi Fujiwara Breakdown of academic impact, for papers by Atsushi Kondo Breakdown of academic impact, for papers by Klaus Eckert Breakdown of academic impact, for papers by Ulf Brockmeier Breakdown of academic impact, for papers by Wojciech Jóźwicki Breakdown of academic impact, for papers by Geethani Bandara Breakdown of academic impact, for papers by Remco van Horssen Breakdown of academic impact, for papers by Marta Compte Breakdown of academic impact, for papers by Richard M. Leimgruber Breakdown of academic impact, for papers by T. Muramatsu
Rankless by CCL
2026